









Markets
/
Stocks
/
nasdaq-fenc
/

Fennec Pharmaceuticals Inc

FENC

8.470USD

-0.290-3.31%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

234.90MMarket Cap

LossP/E TTM



Fennec Pharmaceuticals Inc

8.470

-0.290-3.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Fennec Pharmaceuticals Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fennec Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

60 / 160

Overall Ranking

164 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

13.800

Target Price

+57.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Fennec Pharmaceuticals Inc Highlights

StrengthsRisks

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2996.94% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 47.54M.

Undervalued

The company’s latest PE is -19.27, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.13M shares, decreasing 9.93% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 2.22K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 8.70, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 9.65M, representing a year-over-year increase of 32.91%, while its net profit experienced a year-over-year increase of 43.24%.

Score

Industry at a Glance

Previous score

8.70

Change



Financials

7.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.76

Key Metrics

Free cash flow

No Data

Fennec Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.05, which is lower than the Pharmaceuticals industry's average of 7.22. Its current P/E ratio is -19.27, which is -677.67% below the recent high of 111.31 and -2181.22% above the recent low of -439.57.

Score

Industry at a Glance

Previous score

7.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 60/160

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.80, which is higher than the Pharmaceuticals industry's average of 7.79. The average price target for Fennec Pharmaceuticals Inc is 13.00, with a high of 15.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

13.800

Target Price

+57.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Fennec Pharmaceuticals Inc

FENC

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 6.64, which is lower than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 9.53 and the support level at 7.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.97

Change

-0.33

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.043

Sell

RSI(14)

43.272

Neutral

STOCH(KDJ)(9,3,3)

46.191

Sell

ATR(14)

0.473

Low Volatility

CCI(14)

-60.401

Neutral

Williams %R

74.882

Sell

TRIX(12,20)

-0.147

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

8.800

Sell

MA10

8.698

Sell

MA20

8.917

Sell

MA50

8.870

Sell

MA100

8.642

Sell

MA200

7.545

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 5.79. The latest institutional shareholding proportion is 57.94%, representing a quarter-over-quarter decrease of 22.00%. The largest institutional shareholder is The Vanguard, holding a total of 967.09K shares, representing 3.47% of shares outstanding, with 2.21% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Southpoint Capital Advisors LP

4.08M

ESSETIFIN S.p.A.

3.99M

Sonic GP LLC

2.41M

Solas Capital Management, LLC

2.23M

-0.80%

Rosalind Advisors, Inc.

2.05M

+14.74%

BlackRock Institutional Trust Company, N.A.

1.10M

-3.61%

The Vanguard Group, Inc.

Star Investors

967.09K

+0.26%

State Street Investment Management (US)

336.49K

-0.48%

AIGH Capital Management, LLC.

336.40K

+26.31%

Geode Capital Management, L.L.C.

304.60K

-2.16%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 3.21, which is lower than the Pharmaceuticals industry's average of 5.13. The company's beta value is 0.71. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.